<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02782078</url>
  </required_header>
  <id_info>
    <org_study_id>P140318 / AOR14027</org_study_id>
    <nct_id>NCT02782078</nct_id>
  </id_info>
  <brief_title>Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections</brief_title>
  <acronym>DALARI</acronym>
  <official_title>Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clindamycin and rifampicin are authorized in osteoarticular infection treatment (IDSA
      guidelines) but some interaction is observed. The objective of this study is to evaluate and
      quantify rifampicin interaction on clindamycin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It could suggest modification of recommended doses or incitement to antibiotic dosage. Thus,
      theses antibiotics, if association is allowed, could limit fluoroquinolones prescription and
      avoid some antibiotic resistance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clindamycin AUC (area under curve) at steady state and after rifampicin introduction</measure>
    <time_frame>clindamycin AUC will be evaluated after rifampicin interaction, so at day 14 of introduction</time_frame>
    <description>this AUC of clindamycin will be compared to AUC before rifampicin introduction, at day 0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rifampicin auto induction</measure>
    <time_frame>AUC of rifampicin at day 4 (before autoinduction ant at steady state) and day 14 (after autoinduction)</time_frame>
    <description>rifampicin autoinduction will be studied with rifampicin AUC, according time, for each patient, at day 4 and day 14. Comparison of AUC with student's test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical outcome</measure>
    <time_frame>at day 4, day 14, day 28 (or day 60 if osteosynthesis)</time_frame>
    <description>resolution of symptoms first described (pain, swelling, fever…) with specific scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological outcome</measure>
    <time_frame>at day 4, day 14, day 28 (or day 60 if osteosynthesis)</time_frame>
    <description>resolution of inflammatory syndrome (measure of C reactive protein) and hyperleucocytosis (WBC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects and toxicity: number of participants with treatment related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>at day 2, day 4, day 14, day 28 (or day 60 if osteosynthesis)</time_frame>
    <description>skin lesion, digestive symptoms, clostridium infection, liver cytolysis, hematological disorders (leucopenia, hemolytic anemia, thrombopenia)…</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Staphylococcal Infections</condition>
  <arm_group>
    <arm_group_label>Clindamycin and rifampicin dosages</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blood samples for clindamycin and rifampicin dosages (for each patient)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Clindamycin and rifampicin dosages</intervention_name>
    <description>blood samples for clindamycin and rifampicin dosages (for each patient)</description>
    <arm_group_label>Clindamycin and rifampicin dosages</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients ≥18 years of age

          -  osteoarticular infection

          -  staphylococcus detected in bacteriological sampling

          -  sensibility to rifampicin, erythromycin and clindamycin

          -  active intravenous antibiotherapy against staphylococcus detected in bacteriological
             sampling

        Exclusion Criteria:

          -  septic shock or severe initial sepsis

          -  osteoarticular infection with other microorganism than staphylococcus

          -  contraindication to clindamycin or rifampicin including case of hypersensibility to
             one of these two antibiotics

          -  pre-existing renal insufficiency or severe renal insufficiency (creatinine clearance
             &lt;30 ml/min)

          -  serious cognitive disorders

          -  patient under guardianship, trusteeship or non affiliated to social security or CMU
             (beneficiary or assignee)

          -  refusal to take part in the study and to sign the consent form

          -  pregnancy

          -  lactation

          -  administration of clindamycin or rifampicin within the month before inclusion

          -  treatment with enzymatic inductor or inhibitor within the month before inclusion

          -  participation to another study modifying antibiotic treatment administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiphaine Goulenok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiphaine Goulenok, MD</last_name>
    <phone>00 33 1 40 25 72 89</phone>
    <email>tiphaine.goulenok@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Médecine Interne - Hôpital Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiphaine Goulenok, MD</last_name>
      <phone>00 33 1 40 25 72 89</phone>
      <email>tiphaine.goulenok@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarticular infection</keyword>
  <keyword>rifampicin</keyword>
  <keyword>clindamycin</keyword>
  <keyword>enzymatic induction</keyword>
  <keyword>antibiotherapy resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

